

1 Article

## 2 Immunotherapy and Cannabis: A Harmful Drug Interaction or 3 Reefer Madness?

4 Brian J. Piper<sup>1,2\*</sup>, Maria Tian<sup>1</sup>, Pragosh Saini<sup>1</sup>, Ahmad Higazy<sup>1</sup>, Jason Graham<sup>3</sup>, Christian J. Carbe<sup>1</sup>, and Michael  
5 Bordonaro<sup>1</sup>

6 <sup>1</sup> Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, PA, USA  
7 <sup>2</sup> Center for Pharmacy Innovation & Outcomes, Geisinger, Danville, PA, USA  
8 <sup>3</sup> Department of Mathematics, University of Scranton, Scranton, PA, USA  
9 \* Correspondence: [bjpiper1@geisinger.edu](mailto:bjpiper1@geisinger.edu)

10 **Simple Summary:** Two Israeli studies about medical marijuana potentially interfering with im-  
11 munotherapies like nivolumab for cancer treatment have received substantial attention. However,  
12 there have been anonymous but detailed concerns about these reports on PubPeer. This team at-  
13 tempted to verify the data-analysis and statistics of these two reports and the published correction.  
14 Many findings including some that could impact the statistical conclusions could not be verified.  
15 Of the 22 statistical tests on Table 1 of the prospective report, six could not be repeated using the  
16 same statistics and with the provided N. The p-value on 15 corresponded with that of a different  
17 statistical test than was listed in the methods. Re-analysis also identified some previously unre-  
18 ported significant differences (e.g. age) between cannabis users and non-users at baseline. Further  
19 study of the safety of immunotherapy and cannabis combination may be warranted using patient  
20 groups that have been matched on key demographic and medical variables. 150 / 150 words

21 **Abstract:** A retrospective (N=140) and a prospective (N=102) observational Israeli study by Bar-  
22 Sela and colleagues about cannabis potentially adversely impacting the response to immuno-  
23 therapy have together been cited 191 times including by clinical practice guidelines. There have also  
24 been reports on PubPeer outlining unverifiable information in their statistics and numerous dis-  
25 crepancies calculating percentages. This report attempted to replicate the data-analysis including  
26 non-parametric statistics. Table 1 of the corrected prospective report contained 22 p-values but on-  
27 ly one (4.5%) could be verified, despite the authors being transparent about the N and statistics  
28 employed. Cannabis users were significantly ( $p < .0025$ ) younger than non-users but this was not  
29 reported in the retrospective report. There were also errors in percentage calculations (e.g. 13/34  
30 reported as 22.0% instead of 38.2%). Overall, these observational investigations, and especially the  
31 prospective, appear to contain gross inaccuracies which could impact the statistical decisions (i.e.  
32 significant findings reported as non-significant or vice-versa). Although it is mechanistically plau-  
33 sible that cannabis could have immunosuppressive effects which inhibit the response to immuno-  
34 therapy, these two reports should be viewed cautiously. Larger prospective studies of this pur-  
35 ported drug interaction that account for potential confounds (e.g. greater nicotine smoking among  
36 cannabis users) may be warranted. 198 / 200 words

Citation: To be added by editorial staff during production.

Academic Editor: Firstname  
Lastname

Received: date

Revised: date

Accepted: date

Published: date



Copyright: © 2023 by the authors.

Submitted for possible open access  
publication under the terms and  
conditions of the Creative Commons

Attribution (CC BY) license

([https://creativecommons.org/licenses](https://creativecommons.org/licenses/by/4.0/)

[https://creativecommons.org/licenses](https://creativecommons.org/licenses/by/4.0/)

38 **Keywords:** ipilimumab, marijuana, nivolumab, pembrolizumab

42

Graphical abstract:

43

44

45



## 1. Introduction

The National Academy of Sciences (NAS) 2017 cannabis report [1] provides key information for oncology patients who would like their decision of whether to use medical marijuana to be empirically informed. There was substantial or conclusive evidence that oral cannabinoids were effective for chemotherapy induced nausea and vomiting. Similarly, the NAS rated the strength of the evidence of cannabis or cannabinoids being effective for the treatment of chronic pain as substantial/conclusive. However, evidence was rated as limited that cannabis was effective for improving anxiety symptoms. There was moderate evidence that cannabis and cannabinoids caused a small increased risk for the development of depressive disorders [1]. Evidence was rated insufficient to support or refute cannabinoids as an effective treatment for cancer-associated anorexia-cachexia syndrome [1]. There was also limited evidence of a statistical association between cannabis smoking and decreased production of inflammatory cytokines in healthy individuals [1]. The American Cancer Society does not take position for, or against, use of medical cannabis [2].

Cancer is a complex disease process traditionally managed with medical treatments that have progressed from surgical resection, radiation therapy, chemotherapy, and targeted drug therapy to most recently immunotherapy [3, 4]. Unlike traditional therapy, immunotherapy utilizes monoclonal antibodies, small molecule drugs, adoptive cell therapy, oncolytic viruses, and cancer vaccines to activate the body's innate and adaptive immune responses to produce anticancer effects to kill and eliminate tumor cells [4]. However, tumor cells have adapted the ability to express inhibitory "checkpoint" proteins (i.e., cell surface signaling molecules normally expressed in healthy cells that safeguard against dysregulated immunity capable of subjecting the host to immunodeficiency, autoimmunity, malignancy, or harmful immune responses to infectious agents), resulting in decreased function of antigen-specific T cells and ultimately preventing T cells from recognizing and attacking cancer cells [3, 5]. Checkpoint inhibition therapy is a form of cancer immunotherapy that employs antibodies against T cell or antigen presenting cell surface regulators of immune cell inhibition, (i.e., checkpoint inhibitors), to then activate cytotoxic T cells to assist in the killing of tumor cells [5]. Two major immune checkpoint pathways that are currently targeted in oncologic immunotherapeutics are the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) which regulate T-cell proliferation primarily in lymph nodes early in an immune response, and the programmed cell death protein (PD-1) pathways which suppresses T cells in peripheral tissues later the immune response [5, 6]. Inhibition of these targets, resulting in increased activation of the immune system, has led to new immunotherapies for melanoma, non-small cell lung cancer, and several other cancers [6]. Ipilimumab, an inhibitor of CTLA-4, is approved for the treatment of advanced or unresectable melanoma [3, 7]. Nivolumab and pembrolizumab, both PD-1 inhibitors, are approved to treat patients with advanced or metastatic melanoma, patients with metastatic refractory non-small cell lung cancer, patients with renal cell carcinoma, or patients with Hodgkin's lymphoma (pembrolizumab), or head and neck squamous cell carcinoma (pembrolizumab), or hepatocellular carcinoma (nivolumab) [1, 7]. Atezolizumab, avelumab, and durvalumab are PD-1 ligand (PDL-1) inhibitors approved to treat urothelial carcinoma (all), non-small cell lung cancer (atezolizumab and durvalumab), or Merkel cell carcinoma (avelumab), [3,7].

Two observational studies conducted in Israel and published in 2019 [8] and 2020 [9] identified a potential pharmacodynamic drug interaction between immunotherapy and cannabis. The first, a retrospective report, had a moderate sized sample and compared 89 patients that received the anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy nivolumab to 51 that received nivolumab and cannabis [8]. Multivariate analyses determined that cannabis was associated with a decreased response rate to nivolumab with an Odds Ratio of 3.1. A Google Scholar search conducted 1/25/2024 found that this paper [8] has received 121 citations including by two clinical practice

100 guidelines [10,11] (Table S1). However, despite the results section noting that “As shown  
101 in Table 2, no significant difference was found between the two groups in aspects of de-  
102 mographic and medical characteristics.” [8], an anonymous PubPeer posting in Decem-  
103 ber of 2023 re-analyzed Table 2 using the same statistic and claimed to find four signifi-  
104 cant unreported baseline group differences, one-trend ( $p = .06$ ) towards a baseline group  
105 difference in smoking (a well-established risk factor for a variety of cancers) [12], five  
106 mistakes calculating percentages and four rounding oversights [13]. A subsequent pro-  
107 spective observational report compared 68 immunotherapy patients with 34 immuno-  
108 therapy and cannabis. Median overall survival was 6.4 months among cannabis users  
109 versus 28.5 months for cannabis non-users ( $p < .001$ ) [9]. A Google Scholar search com-  
110 pleted in 12/28/2023 determined that this study [9] has received 71 citations (Table S1).  
111 However, there have again been detailed anonymous PubPeer postings [14, 15] regard-  
112 ing both the original report [9] and the published correction [16]. These claim many dif-  
113 ficulties repeating the non-parametric analyses, three errors in determining percentages,  
114 and 19 rounding issues [15]. The purported challenges in transparently calculating and  
115 interpreting the bi-variate analysis could challenge the conclusion that “no statistically  
116 significant differences were found in the baseline demographic and clinical variables be-  
117 tween the study groups” [9].

118 Two research design issues in this area may warrant particular attention. First, ob-  
119 servational studies with self-selected participants may have important confounds. Many  
120 studies have reported that marijuana users have an increased risk for of nicotine use  
121 [17]. The prospective study [9] did not contain any information on nicotine smoking and  
122 whether the groups were similar on this variable. It would be unfortunate to conclude  
123 that marijuana had negative health outcomes if these were driven by the well-  
124 established consequences of tobacco smoking [12]. Second, analysis of a  $2 \times 2$  table for  
125 non-parametric variables is often completed with a chi-square test [18] although other  
126 statistics were developed for when there is a small N. Different practices have evolved  
127 since Karl Pearson developed the chi-square in 1900 including using Fisher’s exact test  
128 (henceforth Fisher’s, developed in 1930) or chi-square with Yates correction for continui-  
129 ty (henceforth Yates, developed in 1934 [19]) when the smallest cell has an observed val-  
130 ue  $< 5$  [20]. Yates has been criticized for over correcting and providing a p value that is  
131 too large (i.e. overly ‘conservative’) [18]. The *British Medical Journal* (BMJ) offers more  
132 precise guidance [20] “In fourfold tables (i.e. a  $2 \times 2$  contingency table), a  $\chi^2$  test is inap-  
133 propriate if the total of the table is less than 20, or if the total lies between 20 and 40 and  
134 the smallest expected (not observed) value is less than 5. ... An alternative to the  $\chi^2$  test is  
135 known as Fisher’s” (Supplemental Appendix 1). As immunotherapy is a first-line or co-  
136 first line treatment for advanced non-small-cell lung cancer [21], metastatic colorectal  
137 cancer [22], advanced cutaneous melanoma [23], and advanced kidney cancer [24]) and  
138 medical cannabis is often used by cancer patients [25], the goal of this report was to re-  
139 analyze the data from these two reports [8, 9] including the correction [16].

## 140 2. Materials and Methods

141 This investigation involved an effort to verify the statistical analysis based on the  
142 information contained in the retrospective report [8], the prospective report [9], and the  
143 corresponding correction of Table 1 [16]. Most of the re-analyses were completed on the  
144  $2 \times 2$  nonparametric tests and determined whether using the reported N and same test  
145 would result in the same p-value. If the reported p value could be reproduced using the  
146 same statistic as was in the original [8, 9] methods, this was interpreted as verified. If the  
147 reported p value could only be reproduced using a different statistic as was listed in the  
148 methods, this was interpreted as misreported. If the p-value could not be reproduced  
149 with at least three-different statistics (chi-square, Fisher’s, or Yates), this was interpreted  
150 as unverified. Information about the smallest expected N and the total N was obtained  
151 to apply the BMJ guidance [20] on which non-parametric statistic was recommended.  
152 Additional analyses were also completed on whether the percentages were accurately

153 reported using Microsoft Excel. Errors were categorized as: 1) general, defined as the re-  
154 ported and calculated differing by > 1%; 2) floor-rounding: defined as the reported being  
155 lower than the calculated; and 3) ceiling-rounding: defined as the reported being higher  
156 than the calculated. Nonparametric analyses were conducted with GraphPad Prism [26]  
157 with the smallest cell expected values determined with [27]. Pilot testing determined  
158 that 2x2 nonparametric analyses produced identical p-values for Prism, SPSS, and SAS.  
159 A between groups t-test was completed with the mean age, SD, and N provided [8] us-  
160 ing GraphPad Prism [28].

### 161 3. Results

162 The original report provided sufficient information that an attempt could be made  
163 to verify Tables 1-4 [8], Tables 1-3 [9], and the corrected Table 1 [16].

#### 164 3.1. Taha et al. *The Oncologist* 2019;24:549–554 [8]

165 The statistical analysis section noted that “Chi-square test was used to determine  
166 the difference between patients’ characteristics in both groups” and “Two-tailed p val-  
167 ues of .05 were considered statistically significant” [8]. The original Table 1 [8] for THC  $\geq$   
168 10 (yes or no) by progressive disease (yes or no) reported a chi-square  $p = .393$ . Reanaly-  
169 sis revealed a chi-square  $p = .2165$ . However, Fisher’s  $p = .3932$ . Similarly, CBD  $\geq 1$  (yes  
170 or no) by progressive disease reported a chi-square  $p = .116$ . Reanalysis showed a chi-  
171 square = .0885 but a Fisher’s  $p = .1161$  indicating that both p values on Table 1 [8] were  
172 misreported.

173 Although not reported as significant in Table 2 [8], the immunotherapy + cannabis  
174 group were 5.7 years and significantly younger than the immunotherapy only group  
175 ( $t(138) = 3.137$ ,  $p = .0021$ , Figure 1A). Smoking was 16.5% more frequent in the immuno-  
176 therapy + cannabis (56.9%) than the immunotherapy only group (40.4%) but this differ-  
177 ence was not quite significant ( $\chi^2(1) = 3.512$ ,  $p = .0609$ , Figure 1B).

#### 178 3.2 Bar-Sela et al. *Cancers* 2020;12:2447 [9]

179 The statistical analysis section noted “A series of  $\chi^2$  tests or Fisher’s exact tests ...  
180 were conducted to analyze the differences between patients’ characteristics in both  
181 groups. ... We computed 2-tailed p-values, where  $p < 0.05$  was considered a statistically  
182 significant result” [9]. Table 1 [9] reported a non-significant p-value of .05178 for the  
183 non-parametric analysis (chi-square or Fisher’s) of whether immunotherapy was re-  
184 ceived as first line vs second+ line. However, recalculation determined that chi-square  $p =$   
185 .0307 (Figure 1C) and Fisher’s  $p = .0334$ . The cannabis users (76.4%) were significantly  
186 more likely at baseline to receive immunotherapy as 2<sup>nd</sup> line or later treatment than the  
187 cannabis non-users (54.4%). As the total N exceeded 40 and the minimum expected cell  
188 value was 13, the BMJ guidance [20] indicates that chi-square was the appropriate analy-  
189 sis (Table 1). This result was classified as misreported as the recalculated Yates  $p = .0518$ .  
190 Further information on Table 1 may be found in Section 3.3.

191 The results section [9] noted “liver metastasis of the immunotherapy group (I-G) (I-  
192 G 19%) vs. the immunotherapy-cannabis group (IC-G) (67%,  $p = 0.89$ )” which, based on  
193 this p-value, would be interpreted as non-significant. However, reanalysis revealed that  
194 this difference was significant ( $p < .0001$  for chi-square, Fisher’s, and Yates, Figure 1D).

195 Table 2 [9] reported two trends in p-values of abnormal laboratory tests but both  
196 were unverified. For lymphocytes, this was reported as  $p = .08$  but the calculated two-  
197 tailed chi-square was  $p = .1199$ , Fisher’s  $p = .1412$ , and Yates  $p = .1793$ . As the results sec-  
198 tion [9] mentioned a one-tailed p value, calculation of one-tailed values were as follows:  
199 chi-square  $p = .0600$ , Fisher’s  $p = .0890$ , and Yates  $p = .0896$ . Similarly, for Alkaline  
200 Phosphatase, the reported p value ( $p = .09$ ) could not be verified despite six attempts  
201 (two-tailed: chi-square = .1374, Fisher’s = .1468, Yates = .2157; one-tailed chi-square =  
202 .0687, Fisher’s = .1089, Yates = .1079). Further, of the twelve reported percentages, two  
203

204 (16.7%) contained minor rounding issues (12 / 68 reported as 17 but calculated as 17.6%  
205 which would round to 18, and 23 / 34 reported as 67 but calculated as 67.6% which  
206 would round to 68).

207 3.3 Correction to Bar-Sela et al. *Cancers* 2020;12:2447 [16]

208 The correction [16] published in April of 2022 to [9] contained a new Table 1. Of the  
209 22 p-values reported from 2 x 2 analyses, 6 (27.3%) could not be replicated with chi-  
210 square or Fisher's exact test (i.e. the non-parametric statistics listed in the methods) [9] or  
211 with chi-square with Yates correction. However, the p-value on 15 statistical tests did  
212 correspond to four decimal places with that of different statistic (Yates) than was listed  
213 in the methods. Finally, for renal cell carcinoma, the percentages (+ / total) were equal in  
214 both groups (5.9%) and the p-value (1.000) was the same for the chi-square, Yates, and  
215 Fisher's tests (Table 1). Overall, 4.5% of the p-values from Table 1 [16] were verified. Ta-  
216 ble 1 also shows that four analyses had a minimum expected cell value < 5. However, as  
217 the total N (102) was well (> 2.5 fold) above 40, the BMJ guidance [21] indicates that chi-  
218 square would be the appropriate analysis.

219 Table 1 [16] did not list a p-value for the age comparison. However, the data was  
220 reported in a format (median, min – max) that precluded reanalysis of whether the can-  
221 nabis users being three years younger was a significant difference. There were three er-  
222 rors in calculating percentages among cannabis users. Chronic diseases = 0 (13/34) was  
223 reported as 22.0% but calculated as 38.2%. High blood pressure (13/34) was reported as  
224 34.1% but calculated as 38.2%. Brain metastasis (8/34) was reported as 13.2% but calcu-  
225 lated as 23.5% (Table S2). The corrected table [16] contained 19 rounding errors, mostly  
226 floor rounding but there was one case of ceiling rounding of 0.1% (e.g. 55/68 reported as  
227 80.8% but calculated as 80.9%, Table S2).

228

229

230

231

232


233

234

**Table 1.** Results of re-analysis of the Bar-Sela correction [4] with total N = 102 evaluating potential adverse effects of cannabis on immunotherapy using <sup>C</sup>chi-square, <sup>F</sup>Fisher's or <sup>Y</sup>Yates non-parametric statistics. Minimum expected cell N determined with [20]. The British Medical Journal (BMJ) guidance on the recommend non-parametric statistic is reported [11]. Atezo: atezolizumab, COPD: Chronic Obstructive Pulmonary Disease, ECOG: Eastern Cooperative Oncology Group, LC: Lung Cancer, nivo: nivolumab.

Variable	Smallest Cell N observed (expected)	BMJ statistic	Reported p	Calculated p	Inter
Gender	10 (10.67)	chi-square	.9399 <sup>C or F</sup>	.9399 <sup>Y</sup>	Mis
ECOG	10 (7.67)	chi-square	.3568 <sup>C or F</sup>	.3568 <sup>Y</sup>	Mis
Chronic diseases = 0	13 (11.67)	chi-square	.7124 <sup>C or F</sup>	.4908 <sup>C</sup> , .5136 <sup>F</sup> , .6398 <sup>Y</sup>	Un
Chronic diseases = 1	7 (7.67)	chi-square	.9332 <sup>C or F</sup>	.9332 <sup>Y</sup>	Mis
Chronic diseases = 2+	14 (14.67)	chi-square	.9437 <sup>C or F</sup>	.9437 <sup>Y</sup>	Mis
Chronic heart disease	5 (7.67)	chi-square	.2762 <sup>C or F</sup>	.2762 <sup>Y</sup>	Mis
Diabetes	6 (7.67)	chi-square	.5576 <sup>C or F</sup>	.5576 <sup>Y</sup>	Mis
High blood pressure	13 (15.67)	chi-square	.3612 <sup>C or F</sup>	.3612 <sup>Y</sup>	Mis
COPD	3 (4.00)	chi-square	1 <sup>C or F</sup>	.5145 <sup>C</sup> , .7463 <sup>F</sup> , .7445 <sup>Y</sup>	Un
Hyperlipidemia	7 (10.00)	chi-square	.2491 <sup>C or F</sup>	.1436 <sup>C</sup> , .1737 <sup>F</sup> , .2714 <sup>Y</sup>	Un
Other disease	0 (-)	chi-square	1 <sup>C or F</sup>	.3125 <sup>C</sup> , .5512 <sup>F</sup> , .8007 <sup>Y</sup>	Un
Non-small cell LC	14 (15.00)	chi-square	.8325 <sup>C or F</sup>	.8325 <sup>Y</sup>	Mis
Melanoma	9 (11.33)	chi-square	.414 <sup>C or F</sup>	.4140 <sup>Y</sup>	Mis
Renal Cell Carcinoma	2 (2.00)	chi-square	1 <sup>C or F</sup>	1.000 <sup>C, E, Y</sup>	V
Other malignancy	3 (1.67)	chi-square	1 <sup>C or F</sup>	.1946 <sup>C</sup> , .3300 <sup>F</sup> , .4175 <sup>Y</sup>	Un
Brain metastasis	8 (6.67)	chi-square	.6993 <sup>C or F</sup>	.6993 <sup>Y</sup>	Mis
Lungs metastasis	11 (13.33)	chi-square	.4303 <sup>C or F</sup>	.4303 <sup>Y</sup>	Mis
Liver metastasis	11 (8.00)	chi-square	.2157 <sup>C or F</sup>	.2157 <sup>Y</sup>	Mis
Immunotherapy 1 <sup>st</sup> line	8 (13.00)	chi-square	.05178 <sup>C or F</sup>	.0518 <sup>Y</sup>	Mis
Pembrolizumab or nivo	5 (8.67)	chi-square	.127 <sup>C or F</sup>	.1270 <sup>Y</sup>	Mis
Ipilimumab & nivo	4 (6.67)	chi-square	.2517 <sup>C or F</sup>	.2517 <sup>Y</sup>	Mis
Durvalumab or atezo	1 (2.00)	chi-square	1 <sup>C or F</sup>	.3720 <sup>C</sup> , .6607 <sup>F</sup> , .6554 <sup>Y</sup>	Un

235



236

237

238

**Figure 1.** Baseline group differences between cannabis non-users (-) and users (+) based on re-analysis of the reported data in [8] (A, B) and [9] (C, D) #chi-square  $p \leq .061$ , \*chi-square  $p < .05$ , \*\*t-test  $p < .005$ , \*\*\*chi-square  $p < .0001$ .



239 **Table S1.** Examples of studies that have cited the Teha [8] and the Bar-Sela [9] cannabis and immunotherapy manuscripts.

Authors	Journal	Title	Conclusions
Bodine and Kemp [1]	<i>StatPearls</i>	Medical Cannabis Use in Oncology	"when utilizing medicinal marijuana to treat the side effects associated with oncology treatment regimens, clinicians must consider the possibility of cannabinoids interfering with the effectiveness of their patient's cancer therapy"
To et al. [2]	<i>Supportive Care in Cancer</i>	MASCC Guideline: cannabis for cancer-related pain and risk of harms and adverse events	"We recommend against using cannabinoids for any indication in cancer patients undergoing treatment with a checkpoint inhibitor (level of evidence: III; grading of evidence: C; category of guideline: suggestion)"
Ramer et al. [3]	<i>Cancers</i>	Impact of Cannabinoid Compounds on Skin Cancer	"It seems likely that the obvious combination of cannabinoids and checkpoint inhibitors is a rather unfavorable variant of combination therapy"
Abrams et al. [4]	<i>JNCI Monographs</i>	Cancer Treatment: Preclinical & Clinical	"clinicians should now apprise patients embarking on immunotherapy regimens of these findings so they may be aware of the potential risks"
Nugent et al. [5]	<i>Cancer</i>	Medical Cannabis Use Among Individuals with Cancer: An Unresolved and Timely Issue	"The coadministration of cannabinoids and chemotherapeutics with the potential for drug-drug interactions via any of these pathways is discouraged"
Creanga-Murariu et al. [6]	<i>Frontiers in Pharmacology</i>	Should Oncologists Trust Cannabinoids?	"the scarce clinical data available more likely indicate a deleterious effect of cannabinoids on tumors exposed to immunotherapy"
Nahler [7]	<i>Pharmaceutical Medicine</i>	Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics	"Caution is also advised against the use of cannabis by cancer patients during immune therapy with monoclonal antibodies, as this may result in a decrease in time to tumor progression and decreased overall survival"
Abu-Amna et al. [8]	<i>Current Treatment Options in Oncology</i>	Medical Cannabis in Oncology: A Valuable Unappreciated Remedy or an Undesirable Risk?	"In conclusion, we recommend using cannabis with caution in oncology patients being treated with immunotherapy and suggest prescribing cannabis only when there are clear indications and expected benefits"

Sarsembayeva et al. [9]	<i>Frontiers in Oncology</i>	Cannabinoids and endocannabinoids system in immunotherapy: helpful or harmful?	“Likewise, the use of medical cannabis or cannabis-derived products during immunotherapy should be reconsidered as they might interfere with ICLs’ mechanism”
Hinz et al. [10]	<i>British Journal of Cancer</i>	Cannabinoids as anticancer drugs: status of preclinical research	“This study illustrates that cannabis use, in the case via modulation of the immune system, can lead to negative and thus life-threatening effects for cancer patients.”

## 240 Citations

- 241 1. Bodine, M.; Kemp, A.K. *Medical Cannabis Use in Oncology*. In *StatPearls*; StatPearls Publishing: Treasure Island (FL), 2024.
- 242
- 243 2. To, J.; Davis, M.; Sbrana, A.; Alderman, B.; Hui, D.; Mukhopadhyay, S.; Bouleuc, C.; Case, A.A.; Amano, K.; Crawford, G.B.; et al. MASCC Guideline: Cannabis for Cancer-Related Pain and Risk of Harms and Adverse Events. *Support Care Cancer* **2023**, *31*, 202, doi:[10.1007/s00520-023-07662-1](https://doi.org/10.1007/s00520-023-07662-1).
- 244
- 245
- 246 3. Ramer, R.; Wendt, F.; Wittig, F.; Schäfer, M.; Boeckmann, L.; Emmert, S.; Hinz, B. Impact of Cannabinoid Compounds on Skin Cancer. *Cancers (Basel)* **2022**,
- 247 *14*, 1769, doi:[10.3390/cancers14071769](https://doi.org/10.3390/cancers14071769).
- 248
- 249 4. Abrams, D.I.; Velasco, G.; Twelves, C.; Ganju, R.K.; Bar-Sela, G. Cancer Treatment: Preclinical & Clinical. *J Natl Cancer Inst Monogr* **2021**, *2021*, 107–113,
- 250 doi:[10.1093/jncimonographs/lgab010](https://doi.org/10.1093/jncimonographs/lgab010).
- 251
- 252 5. Nugent, S.M.; Meghani, S.H.; Rogal, S.S.; Merlin, J.S. Medical Cannabis Use among Individuals with Cancer: An Unresolved and Timely Issue. *Cancer*
- 253 **2020**, *126*, 1832–1836, doi:[10.1002/cncr.32732](https://doi.org/10.1002/cncr.32732).
- 254
- 255 6. Creanga-Murariu, I.; Filipciuc, L.E.; Cuciureanu, M.; Tamba, B.-I.; Alexa-Stratulat, T. Should Oncologists Trust Cannabinoids? *Frontiers in Pharmacology*
- 256 **2023**, *14*, doi:[10.3389/fphar.2023.1211506](https://doi.org/10.3389/fphar.2023.1211506).
- 257
- 258 7. Nahler, G. Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics. *Pharmaceut Med* **2022**, *36*, 99–129, doi:[10.1007/s40290-022-00420-4](https://doi.org/10.1007/s40290-022-00420-4).
- 259
- 260 8. Abu-Amna, M.; Salti, T.; Khoury, M.; Cohen, I.; Bar-Sela, G. Medical Cannabis in Oncology: A Valuable Unappreciated Remedy or an Undesirable Risk?
- 261 *Curr. Treat. Options in Oncol.* **2021**, *22*, 16, doi:[10.1007/s11864-020-00811-2](https://doi.org/10.1007/s11864-020-00811-2).

262

263

264

265

266

267

9. Sarsembayeva, A.; Schicho, R. Cannabinoids and the Endocannabinoid System in Immunotherapy: Helpful or Harmful? *Front Oncol* **2023**, *13*, 1296906, doi:[10.3389/fonc.2023.1296906](https://doi.org/10.3389/fonc.2023.1296906).
10. Hinz, B.; Ramer, R. Cannabinoids as Anticancer Drugs: Current Status of Preclinical Research. *Br J Cancer* **2022**, *127*, 1–13, doi:[10.1038/s41416-022-01727-4](https://doi.org/10.1038/s41416-022-01727-4).

**Table S2.** Percentages reported from [9] and calculated for Cannabis Users (CU) and Cannabis Non Users (CNU). ECOG: Eastern Conference Oncology Group.

<u>Variable</u>	<u>Numerator</u>	<u>Denominator</u>	<u>Reported %</u>	<u>Calculated %</u>	<u>Difference</u>
Gender-Female (CU)	10	34	29.5%	29.4%	-0.1%
Gender-Male (CU)	24	34	70.5%	70.6%	+0.1%
ECOG $\leq$ 1 (CNU)	55	68	80.8%	80.9%	+0.1%
ECOG $\leq$ 1 (CU)	24	34	70.5%	70.6%	+0.1%
Chronic diseases = 0 (CNU)	22	68	32.3%	32.4%	+0.1%
Chronic diseases = 0 (CU)	13	34	22.0%	38.2%	+16.2%
Chronic diseases = 1 (CU)	7	34	20.5%	20.6%	+0.1%
Chronic diseases = 2 (CU)	14	34	41.1%	41.2%	+0.1%
Chronic heart disease (CNU)	18	68	26.4%	26.5%	+0.1%
High blood pressure (CU)	13	34	34.1%	38.2%	+4.1%
Melanoma (CNU)	25	68	36.7%	36.8%	+0.1%
Melanoma (CU)	9	34	26.4%	26.5%	+0.1%
Renal cell carcinoma (CNU)	4	68	5.8%	5.9%	+0.1%
Renal cell carcinoma (CU)	2	34	5.8%	5.9%	+0.1%
Brain metastasis (CU)	8	34	13.2%	23.5%	+10.3%
Lungs metastasis (CNU)	39	68	57.3%	57.4%	+0.1%
Liver metastasis (CU)	11	34	32.3%	32.4%	+0.1%
Immunotherapy 1 <sup>st</sup> line (CNU)	31	68	45.5%	45.6%	+0.1%
Immunotherapy 2 <sup>nd</sup> line (CU)	26	34	76.4%	76.5%	+0.1%
Pembrolizumab or nivolumab (CU)	29	34	85.2%	85.3%	+0.1%
Ipilimumab or nivolumab (CU)	4	34	11.7%	11.8%	+0.1%
Durvalumab or atezolizumab (CNU)	5	68	7.3%	7.4%	+0.1%

296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343

**Supplementary Appendix 1.** British Medical Journal guidance [20] on the selection of non-parametric statistics for small N.

---

“When the numbers in a 2 x 2 contingency table are small, the  $\chi^2$  approximation becomes poor. The following recommendations may be regarded as a sound guide. In fourfold tables a  $\chi^2$  test is inappropriate if the total of the table is less than 20, or if the total lies between 20 and 40 and the smallest expected (not observed) value is less than 5; in contingency tables with more than one degree of freedom it is inappropriate if more than about one fifth of the cells have expected values less than 5 or any cell an expected value of less than 1. An alternative to the  $\chi^2$  test for fourfold tables is known as Fisher’s Exact test and is described in Chapter 9

When the values in a fourfold table are fairly small a “correction for continuity” known as the “Yates’ correction” may be applied. Although there is no precise rule defining the circumstances in which to use Yates’ correction, a common practice is to incorporate it into  $\chi^2$  calculations on tables with a total of under 100 or with any cell containing a value less than 10.”

---

#### 4. Discussion

The observational studies [8, 9] identifying a potential drug interaction between cannabis and immunotherapy have been widely cited including in clinical practice guidelines [10, 11] and in a publication geared to the general public [2] (Table S1). This report determined that an appreciable subset of the statistics contained in [8, 9] could not be verified and was generally consistent with the PubPeer reports [13-15]. There are a few possibilities that might be able to account for only 4.5% of the p-values in the correction [4] being verified and the many inconsistencies. Analyses in the retrospective report were completed with SPSS, version 21 [8]. The prospective study listed both SAS and R [9]. Although we used GraphPad for our analyses, we feel that it is unlikely that different software would produce such disparate results. Another possibility is that research with humans is challenging and there was a small amount of missing data. We feel this explanation is also unlikely because the correction listed the N for each cell for four variables [9] and there was no missing data. Similarly, verification of the percentages (Table S3) does not indicate that the denominator was decreased. However, we can not discount this possibility for other variables or tables. Another possibility, which we feel is more likely because the p-values correspond to four decimal places on fifteen occasions (Table 1) is that the methods section listed one statistic (chi-square) but a slightly different statistic (chi-square with Yates) was completed. The PubPeer response by a middle author also indicates that Yates was completed [29]. Notably, the BMJ guidance [20] attempted to clarify when to use chi-square, Fisher’s, and Yates. Table 1 suggests that Yates may have been uniformly used, independent of the minimum expected value or the total N. Although the methods section listed “We computed 2-tailed p-values”, as the attempted verification produced p-values that were approximately twice as large (and the results section alluded to a one-tailed test), it is also possible that the reported p-values were one-tailed on Table 2 [4]. Similarly, while the methods section [8] lists “Chi-square test was used to determine the difference between patients’ characteristics

344 in both groups.”, it is likely that some of the reported p-values were from Fisher’s. It is  
345 important for the readers to be informed of which nonparametric statistic was complet-  
346 ed so that they can assess the Type I error rate. There is a general consensus that Yates is  
347 overly cautious in its desire to avoid a type I error [30]. Fisher’s should not be reported if  
348 the total N of all four cells is above 40 (the N was 140 in [Teha]) and the expected N was  
349  $\geq 5$  [20]. Although choosing which non-parametric statistic to use can be challenging  
350 when different resources have contradictory recommendations [31, Supplemental Ap-  
351 pendix 1], at the very least, we believe that telling that audience in the methods that you  
352 will run statistic A but then reporting in the results the findings from statistic B is a non-  
353 trivial oversight.

354 Smoking is a well-established factor for the development of different cancers [12]  
355 which should not be overlooked [9]. In colorectal cancer (CRC), smoking increases the  
356 risk by 59% (OR = 1.59, 95% CI: 1.30–1.94) [31]. Additionally, over 29 pack years of smok-  
357 ing was linked to 61% increased CRC risk (OR = 1.61, 95% CI: 1.31–1.99) compared to  
358 those who never smoked [32]. Similarly, smokers carry a high risk of developing early-  
359 onset colorectal neoplasms (EoCRN) (OR, 1.33; 95% confidence interval [CI], 1.17–1.52)  
360 compared to those who never smoked [33]. Another study analyzed 13,169 cases and  
361 16,010 controls from Europe and Canada and found that male smokers with an average  
362 daily dose of >30 cigarettes had ORs of 103.5 (95% CI 74.8-143.2) for squamous cell carci-  
363 noma (SqCC), 111.3 (95% CI 69.8-177.5) for small cell lung cancer (SCLC), and 21.9 (95%  
364 CI 16.6-29.0) for adenocarcinoma (AdCa). In women, the corresponding ORs were 62.7  
365 (95% CI 31.5-124.6), 108.6 (95% CI 50.7-232.8), and 16.8 (95% CI 9.2-30.6), respectively.  
366 [34] Interestingly, both inherent and acquired attributes of a person such as sex or medi-  
367 cal conditions can also affect the degree of cancer development from smoking. In one  
368 study, patients with hyperglycemia and smoked  $\geq 20$  pack-years had a synergistic effect  
369 on the gallbladder cancer (GBC) risk (all  $P < 0.01$ ) [35]. Additionally, those with diabetes  
370 and smoked  $\geq 20$  pack-years had the highest risk of GBC compared to those with  
371 normoglycemia and never smoked (hazard ratio (HR), 1.658; 95% CI, 1.437–1.914) [36].  
372 Another study using multivariate Cox regression models suggested that male smokers  
373 had a 39% higher risk (HR = 1.39, 95% confidence interval (CI): 1.16, 1.67) of cancer of the  
374 left (distal or descending) colon but not of the right (proximal or ascending) colon (HR =  
375 1.03, 95% CI: 0.89, 1.18), while female ever smokers had a 20% higher risk (HR = 1.20, 95%  
376 CI: 1.06, 1.36) of cancer of the right colon but not of the left colon (HR = 0.96, 95% CI: 0.80,  
377 1.15) [35]. Compared with male smokers, female smokers also had a greater risk of rectal  
378 cancer ( $P$  for heterogeneity = 0.03) [35].

379 Although there were many differences between our findings are those reported  
380 earlier [8, 9, 16], we are not suggesting that anyone has engaged in anything nefarious.  
381 We commend the earlier reports [8, 9] for addressing a timely and important topic. How-  
382 ever, it may also be valuable to prevent situations like this in the future. If the authors are  
383 going to do engage in an atypical practice (e.g. floor rounding [14]), it would be beneficial  
384 to briefly document this in the methods section. It is also possible that floor rounding  
385 was employed for reporting the p-values. About one-third of leading biomedical journals  
386 reported rarely or never using specialized statistical reviews [36]. As the statistical analy-  
387 sis section contained “A series of  $\chi^2$  tests or Fisher’s exact tests (when the assumptions of  
388 the parametric  $\chi^2$  test (sic) were not met)” [9], if there was a statistical reviewer, this per-  
389 son may not have been reading carefully. Emails to the editors asking if these manu-  
390 scripts [8, 9] received a statistical review were not answered. Further, it would be well  
391 beyond standard practice to expect an (often volunteer) reviewer to re-run all the anal-  
392 yses. In psychology, it is common to list the test statistic, the degrees of freedom and the  
393 p-value. An analysis of a quarter million psychology papers revealed that half contained  
394 inconsistencies where the reported test statistic and p-value did not correspond. Further,  
395 one-seventh of papers included gross inconsistencies defined as “the reported p-value  
396 was significant and the computed p-value was not, or vice versa” [37]. Some experi-  
397 mental psychology journals use software to identify statistical irregularities [37]. We are

398 not aware of any biomedical journals which are employing similar software to assess  
399 percentage calculations including rounding errors or non-parametric analyses.

400 Age was not reported as statistically significant in [8] but had a significant difference  
401 ( $p < .002$ ) in our analysis (Figure 1A). This age difference could reflect that cannabis is  
402 psychoactive and providers in Israel may be less likely to prescribe cannabis to older pa-  
403 tients [38]. Alternatively, cannabis users could have had a more aggressive or more ad-  
404 vanced form of cancer at baseline. As the cannabis users were much more likely to have  
405 liver metastasis at baseline (Figure 1D), cannabis may simply be a proxy for a high bur-  
406 den symptomatic disease [38]. Whether immunotherapy was received first or second-  
407 line was reported as non-significant ( $p > .050$ ) in Table 1 [8]) and again in [9]. However,  
408 re-analysis revealed that this baseline difference was significant (Figure 1C). Both of these  
409 findings could be interpreted as gross inaccuracies. In one high-profile instance of a  
410 manuscript with multiple issues, there was a twelve-year interval between the original  
411 MMR vaccine and autism study [39] and the retraction [40]. Journals, including those  
412 with reasonable open-access fees (e.g. *Cancers* is currently 2,900 CHF [41], *The Oncologist*  
413 is currently \$2,500 [42]) need to have sufficient staff to deal with these concerns in a time-  
414 ly fashion. A practice that might be helpful moving forward is to include the full data  
415 and a detailed data dictionary as a supplementary material, either with the published  
416 manuscript or with a preprint, to allow for a second party to verify all analyses. The au-  
417 thor instructions of *Cancers* includes “We encourage all authors of articles published in  
418 MDPI journals to share their research data.” [26]. Similarly, the author guidelines for the  
419 retrospective journal notes “*The Oncologist* strongly encourages authors to make all data  
420 and software code on which the conclusions of the paper rely available to readers.” An  
421 email to the corresponding author requesting the original data was not responded to. It  
422 would also be informative to list the N for all cells in each analysis in a supplementary  
423 appendix to facilitate statistical verification.

424 Basic science investigations are crucial as they can avoid the many potential con-  
425 founds (e.g. age, disease severity, smoking, Figure 1) that are challenging to overcome  
426 with observational reports. A recent report attempted to replicate and extend [8, 9] in  
427 two ways. First, tetrahydrocannabinol did not impact the enhanced survivability to anti-  
428 programmed death ligand 1 antibody treatments in a murine colorectal model. Second,  
429 although advanced non-small cell lung cancer patients using cannabis ( $N = 102$ ) were  
430 significantly younger, more likely to have brain metastasis, and marginally more likely to  
431 have liver metastasis ( $p = .06$ ) at baseline than those that did not ( $N = 99$ ), cannabis did  
432 not significantly impact the survivability following pembrolizumab [39].

433 In balancing the benefits and harms of cannabis for cancer patients [1, 2, 39], a  
434 broader perspective is useful. There has been appreciable work focused on anti-cancer  
435 activity of cannabinoids, including possible use in potentiating immunotherapy [46-50].  
436 Cannabinoids, including cannabigerol (CBG), cannabidiol (CBD), and  
437 tetrahydrocannabinol, have been shown, in vitro and in vivo, to inhibit cancer cell pro-  
438 liferation and metastasis, while also promoting apoptosis and suppressing cancer-  
439 related angiogenesis [47-49]. Cannabinoids may also play a positive role in regulating  
440 aberrant cellular metabolism characteristic of cancer [50]. With respect to the role of can-  
441 nabinoids in potentially potentiating immunotherapy in colorectal cancer, these agents  
442 may boost immunogenicity through cytotoxic effects on cancer cells and the subsequent  
443 release of antigens, as well as reprogramming immune cells to target tumors [49]. Given  
444 the various mechanisms by which cannabinoids may have anti-cancer effects, it is im-  
445 portant not to dismiss potential benefits based on possibly unverifiable statistical inter-  
446 pretation of data. In addition, the Taha [8] and Bar-Sela [9, 16] studies involved a limited  
447 number of cancer types, which should not be considered universally applicable for can-  
448 cer immunotherapy in general. It should also be noted that effects of cannabinoids on  
449 immunotherapy may not only be influenced by cancer type but by the concentration of  
450 the relevant agents. For example, while higher concentrations of THC had immunosup-  
451 pressive effects in vitro and in vivo, lower concentrations were immunostimulatory [26].

All of these facts recommend caution in the interpretation of the Taha [8] and Bar-Sela [9, 16] studies as well as other naturalistic investigations where the cannabis route of administration and THC concentration are not homogenous.

One limitation of this report is that only a subset of the originally reported findings could be assessed for veracity because the full raw data was unavailable. Therefore, we can not infer whether the figures contain verifiable, misreported, or unverifiable information. As noted above, we can not discount the possibility that the Israeli team [29] also used floor rounding to report their p-values (e.g.  $p = .0896$  reported as .08) so some analysis that were classified as unverified may in fact be misreported instead. There are many statisticians that would argue that it is ridiculous to interpret the results of a study with  $p = .055$  differently than  $p = .045$ . Dividing results of hypothesis tests into 'significant' and 'non-significant' is both unhelpful and outdated [51]. Although we would concur with the thrust of this argument, findings like Table 1 [8] where age is described as non-significant (i.e.  $p > .05$ ) but then has a recalculated p-value of .0021 or the liver metastasis which was reported as " $p = .89$ " but was calculated as  $p \leq .0001$  are more concerning as they obscure the reader's ability to accurately determine whether the cannabis users and non-user groups were equivalent at baseline.

## 5. Conclusions

In conclusion, reanalysis of a subset of the reported information in the very influential observational reports purporting to show a harm inducing drug interaction between immunotherapy and cannabis [8, 9, 15], was unable to verify many of the analyses and there were some gross inaccuracies. This reanalysis and Figure 1 calls into question the conclusion that "no statistically significant differences were found in the baseline demographic and clinical variables between the study groups" [9]. Future prospective studies on this topic could consider matching on key demographic or medical condition variables. Due to the well-known contribution of smoking to cancer in a variety of tissues [12], excluding participants who are current or former nicotine smokers, or at least stratifying a homogenous sample with one cancer type accordingly, might be informative. Perhaps more important would be strengthening practices [51] to prevent similar situations [52, 53] from occurring. This could include registering the methods, making the raw data publicly available, and developing and implementing statistical software that could assist manuscript reviewers in identifying irregularities in the reporting of descriptive and bivariate analyses.

## 6. Patents

Not applicable.

**Supplementary Materials:** The following supporting information can be downloaded at: [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Table S1, S2, and Supplementary Appendix.

**Author Contributions:** Conceptualization, B.J.P.; methodology, B.J.P.; software, M.T.; validation, X.X., Y.Y. and Z.Z.; formal analysis, B.J.P.; investigation, B.J.P, M.T.; resources, X.X.; data curation, X.X.; writing—original draft preparation, B.J.P., C.J.C., A.H, J.G., M.T., & M.B.; writing—review and editing, B.J.P. C.J.C, & M.B.; visualization, B.J.P, M.T.; supervision, X.X.; project administration, X.X.; funding acquisition, B.J.P. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Pennsylvania Academic Clinical Research Center.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All of the information used in this manuscript is publicly available at [8, 9, 16].



501 **Acknowledgments:** Thanks to Amy Allison, MLS for technical support, Christina M. Gregor and  
502 Alysha Lopez, PharmD for feedback on an earlier version of this manuscript, and Mellar Davis,  
503 MD for his deep insights on this topic.

504 **Conflicts of Interest:** MT and BJP were supported by the Pennsylvania Academic Clinical Re-  
505 search Center. Software used for figure construction was provided by NIEHS (T32 ES007060-  
506 31A1). The other authors declare no conflicts of interest. The funders had no role in the design of  
507 the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or  
508 in the decision to publish the results.

## 509 References

- 510 1. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. *The Na-*  
511 *tional Academies Press*, 2017.
- 512 2. The Editors of Mayo Clinic. Mayo Clinic Medical Marijuana. *Mayo Clinic*, 2023.
- 513 3. Haynes B.F., & Soderberg K.A., & Fauci A.S. Mechanisms of regulation and dysregulation of the immune system.  
514 Loscalzo J, & Fauci A, & Kasper D, & Hauser S, & Longo D, & Jameson J(Eds.), [publicationyear2] Harrison's Principles of  
515 Internal Medicine, 21e. McGraw-Hill Education.  
516 <https://accessmedicinehmedical.com.geihsl.idm.oclc.org/content.aspx?bookid=3095&sectionid=265430844>
- 517 4. Liu C, Yang M, Zhang D, Chen M, Zhu D. Clinical cancer immunotherapy: Current progress and prospects. *Front*  
518 *Immunol.* 2022 Oct 11;13:961805. doi: 10.3389/fimmu.2022.961805. PMID: 36304470; PMCID: PMC9592930.
- 519 5. Eno J. Immunotherapy Through the Years. *J Adv Pract Oncol.* 2017 Nov-Dec;8(7):747-753. Epub 2017 Nov 1. PMID:  
520 30333937; PMCID: PMC6188092.
- 521 6. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.  
522 *Am J Clin Oncol.* 2016 Feb;39(1):98-106. doi: 10.1097/COC.000000000000239. PMID: 26558876; PMCID: PMC4892769.
- 523 7. 5. ACA American Cancer Society (2022). Immune checkpoint inhibitors and their side effects. Retrieved from  
524 <https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html>  
525 <http://www.cancer.org/cancer/cancercauses/geneticsandcancer/index>
- 526 8. Taha, T.; Meiri, D.; Talhamy, S.; Wollner, M.; Peer, A.; Bar-Sela, G. Cannabis Impacts Tumor Response Rate to Nivolumab  
527 in Patients with Advanced Malignancies. *Oncologist*, 2019; 24(4):549-554.
- 528 9. Bar-Sela, G.; Cohen, I.; Campisi-Pinto, S.; Lewitus, GM.; Oz-Ari, L.; Jehassi, A.; Peer, A.; Turgeman, I.; Vernicova, O.;  
529 Berman, P.; Wollner, M.; Moskovitz, M.; Meiri, D. Cannabis Consumption Used by Cancer Patients during Immunother-  
530 apy Correlates with Poor Clinical Outcome. *Cancers (Basel)*, 2020;12(9):2447.
- 531 10. Alderman, B.; Hui, D.; Mukhopadhyay, S.; Bouleuc, C.; Case, AA.; Amano, K.; Crawford, GB.; de Feo, G.; Sbrana, A.;  
532 Tanco, K.; To, J.; Garsed, J.; Davis, M. Multinational Association of Supportive Care in Cancer (MASCC) expert opin-  
533 ion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer. *Support Care*  
534 *Cancer* 2022; 31(1):39.
- 535 11. To, J.; Davis, M.; Sbrana, A.; Alderman, B.; Hui, D.; Mukhopadhyay, S.; Bouleuc, C.; Case, AA.; Amano, K.; Crawford,  
536 GB.; de Feo, G.; Tanco, K.; Garsed, J. MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse  
537 events. *Support Care Cancer*, 2023; 31(4):202.
- 538 12. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health  
539 Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. *Centers for Disease Control and Preven-*  
540 *tion (US)*, 2014.
- 541 13. <https://pubpeer.com/publications/85A8F34A338C7E670E8086BBAA31F4>
- 542 14. <https://pubpeer.com/publications/366C4360C23B9E177F00CA965630F3>
- 543 15. <https://pubpeer.com/publications/5AFA302155D8AE02603134F556A085>
- 544 16. Bar-Sela G, Cohen I, Campisi-Pinto S, Lewitus GM, Oz-Ari L, Jehassi A, Peer A, Turgeman I, Vernicova O, Berman P,  
545 Wollner M, Moskovitz M, Meiri D. Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during  
546 Immunotherapy Correlates with Poor Clinical Outcome. *Cancers* 2020, 12, 2447. *Cancers (Basel)*. 2022;14(8):1957. doi:  
547 10.3390/cancers14081957.
- 548 17. Martell, K.; Fairchild, A.; LeGerrier, B.; Sinha, R.; Baker, S.; Liu, H.; Ghose, A.; Olivotto, I.A.; Kerba, M. Rates of Cannabis  
549 Use in Patients with Cancer. *Curr. Oncol*, 2018; 25, 219-225.
- 550 18. Franke, T. M.; Ho, T.; Christie, C. A. The Chi-Square Test: Often Used and More Often Misinterpreted. *American Journal of*  
551 *Evaluation*, 2012; 33(3), 448-458.
- 552 19. Yates, F. Contingency Tables Involving Small Numbers and the  $\chi^2$  Test. *Supplement to the Journal of the Royal Statistical So-*  
553 *ciety*, 1934; 1(2): 217-235.
- 554 20. BMJ. 8. The Chi squared tests | The BMJ.com. Available online: [https://www.bmj.com/about-bmj/resources-](https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/8-chi-squared-tests)  
555 [readers/publications/statistics-square-one/8-chi-squared-tests](https://www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/8-chi-squared-tests) (accessed on 2019)
- 556 21. UpToDate.com. Available online: [https://www.uptodate.com/contents/overview-of-the-initial-treatment-and-prognosis-](https://www.uptodate.com/contents/overview-of-the-initial-treatment-and-prognosis-of-lung-cancer)  
557 [of-lung-cancer](https://www.uptodate.com/contents/overview-of-the-initial-treatment-and-prognosis-of-lung-cancer) (accessed on 2019)

- 558 22. UpToDate.com. Available online: [https://www.uptodate.com/contents/systemic-therapy-for-nonoperable-metastatic-](https://www.uptodate.com/contents/systemic-therapy-for-nonoperable-metastatic-colorectal-cancer-selecting-the-initial-therapeutic-approach#)  
559 [colorectal-cancer-selecting-the-initial-therapeutic-approach#](https://www.uptodate.com/contents/systemic-therapy-for-nonoperable-metastatic-colorectal-cancer-selecting-the-initial-therapeutic-approach#) (accessed on 2019)
- 560 23. UpToDate.com. Available online: [https://www.uptodate.com/contents/overview-of-the-management-of-advanced-](https://www.uptodate.com/contents/overview-of-the-management-of-advanced-cutaneous-melanoma)  
561 [cutaneous-melanoma](https://www.uptodate.com/contents/overview-of-the-management-of-advanced-cutaneous-melanoma) (accessed on 2019)
- 562 24. UpToDate.com. Available online: [https://www.uptodate.com/contents/systemic-therapy-of-advanced-clear-cell-renal-](https://www.uptodate.com/contents/systemic-therapy-of-advanced-clear-cell-renal-carcinoma)  
563 [carcinoma](https://www.uptodate.com/contents/systemic-therapy-of-advanced-clear-cell-renal-carcinoma) (accessed on 2019)
- 564 25. Tanasescu, R.; Constantinescu, CS. Cannabinoids and the immune system: an overview. *Immunobiology*, 2010; 215(8):588-  
565 97.
- 566 26. Analyze a 2x2 contingency table. Available online: <https://www.graphpad.com/quickcalcs/contingency1/> (accessed on  
567 2019)
- 568 27. Chi Square Calculator 2x2. Available online: <https://www.socscistatistics.com/tests/chisquare/> (accessed on 2019)
- 569 28. Graphpad. GraphPad QuickCalcs: t test calculator. Available online: <https://www.graphpad.com/quickcalcs/ttest1/> (ac-  
570 cessed on 2019)
- 571 29. <https://pubpeer.com/publications/366C4360C23B9E177F00CA965630F3>
- 572 30. Campbell, I. Chi-squared and Fisher–Irwin tests of two-by-two tables with small sample recommendations. *Statistics in*  
573 *Medicine*, 2007; 26(19):3661–75.
- 574 31. Pesch, B.; Kendzia, B.; Gustavsson, P.; Jöckel, KH.; Johnen, G.; Pohlbeln, H.; Olsson, A.; Ahrens, W.; Gross, IM.; Brüske,  
575 I.; Wichmann, HE.; Merletti, F.; Richiardi, L.; Simonato, L.; Fortes, C.; Siemiatycki, J.; Parent, ME.; Consonni, D.; Landi,  
576 MT.; Caporaso, N.; Zaridze, D.; Cassidy, A.; Szeszenia-Dabrowska, N.; Rudnai, P.; Lissowska, J.; Stücker, I.; Fabianova,  
577 E.; Dumitru, RS.; Bencko, V.; Foretova, L.; Janout, V.; Rudin, CM.; Brennan, P.; Boffetta, P.; Straif, K.; Brüning, T. Cigarette  
578 smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control  
579 studies. *Int J Cancer*, 2012;131(5):1210-9.
- 580 32. Amitay, E.L.; Carr, P.R.; Jansen, L.; et al. Smoking, alcohol consumption and colorectal cancer risk by molecular patholog-  
581 ical subtypes and pathways. *Br J Cancer* 122, 2020;1604–1610.
- 582 33. Gram, IT.; Park, SY.; Wilkens, LR.; Haiman, CA.; Le Marchand, L. Smoking-Related Risks of Colorectal Cancer by Ana-  
583 tomical Subsite and Sex. *Am J Epidemiol*, 2020;189(6):543-553.
- 584 34. Li, Q.; Weitz, J.; Li, C.; et al. Smoking as a risk factor for colorectal neoplasms in young individuals? A systematic meta-  
585 analysis. *Int J Colorectal Dis* 38, 2023; 114.
- 586 35. Park, JH.; Hong, JY.; Han K. Threshold dose–response association between smoking pack-years and the risk of gallblad-  
587 der cancer: A nationwide cohort study. *European Journal of Cancer*, 2023;180:99–107.
- 588 36. Hardwicke, TE.; Goodman, SN. How often do leading biomedical journals use statistical experts to evaluate statistical  
589 methods? The results of a survey. *PLOS ONE*, 2020; 15(10): e0239598.
- 590 37. Nuijten MB, Hartgerink CH, van Assen MA, Epskamp S, Wicherts JM. The prevalence of statistical reporting errors in  
591 psychology (1985-2013). *Behavioral Res Methods*. 2016;48(4):1205-1226.
- 592 38. Nuijten, MB.; Polanin, JR. "statcheck": Automatically detect statistical reporting inconsistencies to increase reproducibility  
593 of meta-analyses. *Res Synth Methods*, 2020; 11(5):574-579.
- 594 39. Waissengrin, B.; Leshem, Y.; Taya, M.; Meiri, D.; Merimsky, O.; Shamai, S.; Wolf, I.; Rubinek, T. The use of medical can-  
595 nabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief? *Eur J Cancer*, 2023;  
596 180:52-61.
- 597 40. Wakefield, AJ.; Murch, SH.; Anthony, A.; Linnell, J.; Casson, DM.; Malik, M.; Berelowitz, M.; Dhillon, AP.; Thomson,  
598 MA.; Harvey, P.; Valentine, A.; Davies, SE.; Walker-Smith, JA. Ileal-lymphoid-nodular hyperplasia, non-specific colitis,  
599 and pervasive developmental disorder in children. *Lancet*, 1998; 351(9103):637-41. Erratum in: *Lancet*. 2004;363(9411):750.
- 600 41. Wakefield, AJ.; Murch, SH.; Anthony, A.; Linnell, J.; Casson, DM.; Malik, M.; Berelowitz, M.; Dhillon, AP.; Thomson,  
601 MA.; Harvey, P.; Valentine, A.; Davies, SE.; Walker-Smith, JA. Retraction: Ileal-lymphoid-nodular hyperplasia, non-  
602 specific colitis, and pervasive developmental disorder in children. *Lancet*. 2010;375(9713):445.
- 603 42. [https://www.mdpi.com/journal/cancers/apc#:~:text=All%20articles%20published%20in%20Cancers,papers%20accepted%  
604 20after%20peer%20review](https://www.mdpi.com/journal/cancers/apc#:~:text=All%20articles%20published%20in%20Cancers,papers%20accepted%20after%20peer%20review) (accessed 1/26/2024)
- 605 43. <https://academic.oup.com/oncolo/pages/open-access> (accessed 1/26/2024)
- 606 44. <https://www.mdpi.com/journal/cancers/instructions#suppmaterials> (accessed on 2024)
- 607 45. Hinz, B.; Ramer, R. Anti-tumour actions of cannabinoids. *Br J Pharmacol*, 2019; 176(10):1384-1394.
- 608 46. Kovalchuk, O.; Kovalchuk, I. Cannabinoids as anticancer therapeutic agents. *Cell Cycle*, 2020; 19(9):961-989.
- 609 47. Laezza, C.; Pagano, C.; Navarra, G.; Pastorino, O.; Proto, MC.; Fiore, D.; Piscopo, C.; Gazzo, P.; Bifulco, M. The  
610 Endocannabinoid System: A Target for Cancer Treatment. *Int J Mol Sci*, 2020; 21(3):747.
- 611 48. Zaiachuk, M.; Pryimak, N.; Kovalchuk, O.; Kovalchuk, I. Cannabinoids, Medical Cannabis, and Colorectal Cancer Immu-  
612 notherapy. *Front Med (Lausanne)*, 2021; 8:713153.
- 613 49. Sun, D.; Li, X.; Nie, S.; Liu, J.; Wang, S. Disorders of cancer metabolism: The therapeutic potential of cannabinoids. *Bio-*  
614 *med Pharmacother*. 2023; 157:113993.
- 615 50. Stuart, H.; Hurlbert, R.; Levine & Jessica, U. Coup de Grâce for a Tough Old Bull: “Statistically Significant” Expires. *The*  
616 *American Statistician*, 2019; 352-357.

- 617        51. Besançon, L., Peiffer-Smadja, N., Segalas, C. et al. Open science saves lives: lessons from the COVID-19 pandemic. *BMC*  
618        *Med Res Methodol* 21, 2021.
- 619        52. Ioannidis, JPA. Why Most Published Research Findings Are False. *PLoS Medicine*, 2005; 2(8): e124.  
620  
621